Clinical Trials Logo

Filter by:
NCT ID: NCT00751621 Completed - Clinical trials for Primary Immunodeficiency (PID)

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Start date: August 2008
Phase: Phase 3
Study type: Interventional

This study is a continuation of the study ZLB06_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.

NCT ID: NCT00751114 Completed - Clinical trials for Diabetes Mellitus, Type 2

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients

EASIE
Start date: November 2008
Phase: Phase 4
Study type: Interventional

The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period. Secondary objective was to assess the effect of insulin glargine in comparison with sitagliptin on: - HbA1c level - Fasting Plasma Glucose (FPG) - 7-point plasma glucose (PG) profiles - Percentage of patients with HbA1c <7% and <6.5% Safety objectives consisted of: - Hypoglycemia occurrence - Body weight - Overall safety

NCT ID: NCT00750880 Completed - Clinical trials for Rheumatoid Arthritis

An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.

Start date: September 2008
Phase: Phase 3
Study type: Interventional

This open-label, single arm study will investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biologic disease modifying antirheumatic drugs (DMARDs), in patients with severe active RA. Patients will receive tocilizumab 8mg/kg iv as a 60 minute infusion every 4 weeks for a total of 6 infusions. The anticipated time on study treatment is 3-12 months, and the target sample size is >500 individuals.

NCT ID: NCT00750113 Completed - Hypertension Clinical Trials

Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.

Start date: October 2007
Phase: Phase 4
Study type: Interventional

Patients having uncontrolled or poorly controlled hypertension are at risk of experiencing cardiovascular events such as myocardial infarction or stroke. To reduce this risk an appropriate antihypertensive therapy should allow to reach a target blood pressure of less than 130/80 mmHg in order to maximise cardiovascular protection.The purpose of this study is to evaluate the efficacy in blood pressure control when anti-hypertensive therapy is initiated with a combination of low dose Nifedipine GITS and Telmisartan compared to a regimen starting with monotherapy before adding the other drug.The primary efficacy parameter will be the 24 hour mean systolic Blood Pressure on Ambulatory Blood Pressure Monitoring (ABPM) at 16 weeks of treatment compared to baseline

NCT ID: NCT00749996 Completed - Back Pain Clinical Trials

Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease

Start date: November 2006
Phase: Phase 4
Study type: Interventional

The study aims at assessing the short and long-term effectiveness and patient perception of benefit with the use of a DIAMâ„¢ Spinal Stabilization System in the treatment of complex disc disease at a single level from L2 to L5.

NCT ID: NCT00749970 Completed - Schizophrenia Clinical Trials

Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia

SWN-K
Start date: July 2008
Phase: N/A
Study type: Observational

Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.

NCT ID: NCT00749190 Completed - Clinical trials for Diabetes Mellitus, Type 2

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM with insufficient glycemic control. In addition, there will be an open-label treatment arm with sitagliptin (JanuviaTM) as add-on therapy to metformin.

NCT ID: NCT00744497 Completed - Prostatic Neoplasms Clinical Trials

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

READY
Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.

NCT ID: NCT00743938 Completed - Clinical trials for Non Small Cell Lung Cancer

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib

NCT ID: NCT00742950 Completed - Cataract Clinical Trials

Refractive Change Induced by 2.8-mm Corneal Incision

CINPHA
Start date: August 2008
Phase: N/A
Study type: Interventional

The investigators' purpose is to study the induced refractive change caused by different 2.8-mm corneal incision locations in phacoemulsification, because the investigators hypothesize that the effect may be different for nasal, temporal, and superior location, although they are considered astigmatism neutral. Patients will be randomized to nasal or temporal incision, or assigned to superior incision, depending on preexisting astigmatism. Visual acuity, refraction, keratometry, Pentacam analysis, intraocular pressure, biomicroscopy, and funduscopy, will be carried out before and after phacoemulsification. Outcome measures will be induced corneal refractive change (Fourier power vector analysis), ISV change, and visual acuity, at 6 months.